Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition.
Schmidt JA., Fensom GK., Rinaldi S., Scalbert A., Appleby PN., Achaintre D., Gicquiau A., Gunter MJ., Ferrari P., Kaaks R., Kühn T., Floegel A., Boeing H., Trichopoulou A., Lagiou P., Anifantis E., Agnoli C., Palli D., Trevisan M., Tumino R., Bueno-de-Mesquita HB., Agudo A., Larrañaga N., Redondo-Sánchez D., Barricarte A., Huerta JM., Quirós JR., Wareham N., Khaw K-T., Perez-Cornago A., Johansson M., Cross AJ., Tsilidis KK., Riboli E., Key TJ., Travis RC.
BACKGROUND: Little is known about how pre-diagnostic metabolites in blood relate to risk of prostate cancer. We aimed to investigate the prospective association between plasma metabolite concentrations and risk of prostate cancer overall, and by time to diagnosis and tumour characteristics, and risk of death from prostate cancer. METHODS: In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition, pre-diagnostic plasma concentrations of 122 metabolites (including acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose and sphingolipids) were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit) and compared between 1077 prostate cancer cases and 1077 matched controls. Risk of prostate cancer associated with metabolite concentrations was estimated by multi-variable conditional logistic regression, and multiple testing was accounted for by using a false discovery rate controlling procedure. RESULTS: Seven metabolite concentrations, i.e. acylcarnitine C18:1, amino acids citrulline and trans-4-hydroxyproline, glycerophospholipids PC aa C28:1, PC ae C30:0 and PC ae C30:2, and sphingolipid SM (OH) C14:1, were associated with prostate cancer (p